The price of Rubius Therapeutics Inc. (NASDAQ:RUBY) shares last traded on Wall Street fell -19.57% to $0.19.
Based on available information, 1 analysts follow Rubius Therapeutics Inc. (NASDAQ:RUBY). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $3.00 and a low of $3.00, we find $3.00. Given the previous closing price of $0.24, this indicates a potential upside of 1150.0 percent. RUBY stock price is now -21.30% away from the 50-day moving average and -83.85% away from the 200-day moving average. The market capitalization of the company currently stands at $16.74M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 1 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $3.00 as their price target over the next twelve months.
, while ‘SVB Leerink’ rates the stock as ‘Mkt Perform’.
In other news, Appelhans Dannielle, Chief Operating Officer sold 5,737 shares of the company’s stock on Aug 10. The stock was sold for $4,590 at an average price of $0.80. Upon completion of the transaction, the Chief Operating Officer now directly owns 6,763 shares in the company, valued at $1284.97. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 21, Director Epstein David R bought 30,000 shares of the business’s stock. A total of $43,329 was incurred on buying the stock at an average price of $1.44. This leaves the insider owning 4,720,012 shares of the company worth $0.9 million. Insiders disposed of 17,716 shares of company stock worth roughly $3366.04 over the past 1 year. A total of 5.51% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RUBY stock. A new stake in Rubius Therapeutics Inc. shares was purchased by JACOBS LEVY EQUITY MANAGEMENT, INC during the first quarter worth $104,000. INDEXIQ ADVISORS LLC invested $15,000 in shares of RUBY during the first quarter. In the first quarter, TWO SIGMA SECURITIES, LLC acquired a new stake in Rubius Therapeutics Inc. valued at approximately $6,000. MAN GROUP PLC acquired a new stake in RUBY for approximately $6,000. VIRTU FINANCIAL LLC purchased a new stake in RUBY valued at around $5,000 in the second quarter. In total, there are 107 active investors with 76.60% ownership of the company’s stock.
A candlestick chart of Rubius Therapeutics Inc. (NASDAQ: RUBY) showed a price of $0.2219 on Thursday morning. During the past 12 months, Rubius Therapeutics Inc. has had a low of $0.14 and a high of $10.47. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.40, and a quick ratio of 3.40. The fifty day moving average price for RUBY is $0.2445 and a two-hundred day moving average price translates $1.1910 for the stock.
The latest earnings results from Rubius Therapeutics Inc. (NASDAQ: RUBY) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.49, beating analysts’ expectations of -$0.53 by 0.04. This compares to -$0.55 EPS in the same period last year. The company reported revenue of $61.58 million for the quarter, compared to $50.05 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 23.04 percent.
Rubius Therapeutics Inc.(RUBY) Company Profile
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
